We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×

Home > News > Policy

DEA Claims to be Taking Action to Expedite Applications to Study Schedule 1 Drugs

Published: Feb 09, 2018   

Complete the form below and we will email you a PDF version of "DEA Claims to be Taking Action to Expedite Applications to Study Schedule 1 Drugs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Analytical Cannabis?

Analytical Cannabis Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DEA Claims to be Taking Action to Expedite Applications to Study Schedule 1 Drugs

The Drug Enforcement Administration is streamlining the application process for researchers who study or wish to study Schedule I substances not currently approved for medical use. Schedule I drugs are defined as drugs, substances, or chemicals with no accepted medical use and a high potential for abuse, such as ecstasy or LSD.


By taking the process online, both existing and new researchers can submit their applications through a dedicated web portal, improving efficiency and security.


The Controlled Substances Act requires an individual who wishes to conduct research on substances listed in Schedule I to register with DEA. Applicants must provide information about their qualifications, research protocol, and institution where the research will take place. 


“We are committed to finding new and innovative ways to meet the needs of the research community,” said Acting DEA Administrator Robert W. Patterson. “Research is the bedrock of science, and we will—as we have for many years—continue to support and promote legitimate research with Schedule I controlled substances.”


As of December 2017, more than 590 researchers were registered with DEA to study Schedule I substances. Every researcher who has submitted a valid research proposal has been approved. Many researchers conduct multiple research protocols, so the number of approved studies with Schedule I substances exceeds the number of registered researchers.


This article has been republished from materials provided by DEA. Note: material may have been edited for length and content. For further information, please contact the cited source.

 

Like what you just read? You can find similar content on the topic tags shown below.

Policy Science & Health

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement